Finally, deferoxamine mesylate and its parent compound deferoxamine were identified as candidate inhibitors of SMARCAL1 activity, showing significant ability to inhibit proliferation and the downstream protein YAP1.<h4>Conclusion</h4>Targeting SMARCAL1 could be a promising strategy for liver cancer treatment. Here, SMARCAL1 is linked to liver cancer.